US 12,296,048 B2
Polymer particles for neutrophil injury
Omolola Eniola-Adefeso, Ann Arbor, MI (US); William Kelley, Ann Arbor, MI (US); and Theodore Standiford, Ann Arbor, MI (US)
Assigned to The Regents of the University of Michigan, Ann Arbor, MI (US)
Filed by THE REGENTS OF THE UNIVERSITY OF MICHIGAN, Ann Arbor, MI (US)
Filed on Nov. 27, 2023, as Appl. No. 18/519,530.
Application 17/481,525 is a division of application No. 16/920,238, filed on Jul. 2, 2020, granted, now 11,376,221, issued on Jul. 5, 2022.
Application 18/519,530 is a continuation of application No. 17/481,525, filed on Sep. 22, 2021, granted, now 11,826,469.
Claims priority of provisional application 62/870,879, filed on Jul. 5, 2019.
Prior Publication US 2024/0197638 A1, Jun. 20, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/19 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61M 25/01 (2006.01); A61M 25/09 (2006.01)
CPC A61K 9/1647 (2013.01) [A61K 9/0019 (2013.01); A61K 9/1682 (2013.01); A61K 9/19 (2013.01); A61M 25/01 (2013.01); A61M 2025/091 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A pharmaceutical composition comprising at least one rod-shaped Poly-A particle wherein Poly-A is salicylate polyanhydride ester that hydrolyzes to salicylic acid, wherein said Poly-A particle is a vascular-targeted Poly-A particle (VTP), wherein a surface of said VTP is bound with an antibody or ligand that targets one or more proteins expressed on a vascular wall and a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable formulation.